首页> 美国卫生研究院文献>Journal of Clinical and Diagnostic Research : JCDR >Tackling the Problems of Tumour Chemotherapy by Optimal Drug Scheduling
【2h】

Tackling the Problems of Tumour Chemotherapy by Optimal Drug Scheduling

机译:通过最佳药物调度解决肿瘤化疗的问题

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Introduction: There are various strategies for overcoming the major pitfalls of cancer chemotherapy, such as toxicity and drug resistance. The scientific computing of drug scheduling by optimisation before drug administration is one among them. In a majority of these strategies, the pharmacodynamic variations are given more importance than the pharmacokinetic variations. This study was meant to analyse the importance of the pharmacokinetic parameters (φ) of the individual patients in cancer chemotherapy scheduling, along with the pharmacodynamic factors.>Methods: A mathematical model is developed and it is implemented in the open source OCTAVE GNU LINUX. Optimisation is done by using an optimization tool in OCTAVE. The present study was aimed at evaluating the daily drug dosaging and cyclic chemotherapy which are commonly practised in the chemotherapy scheduling. Four cases were analyzed with and without considering the pharmacokinetic parameters. The optimal therapy was meant to reduce the number of cancer cells to a minimum at the end of the therapy and to minimise the emergence of resistant cancer cells. Since the dose was within tolerable limits, the toxic effects could also be minimised.>Results: Even with the consideration of a 1 per cent effect (φ), the maximum possible dose and the performance index were increased in the daily scheduling. But in the cyclic therapy, even though the maximum tolerated dose or the performance index was not altered, the cumulative toxicity was greatly reduced.>Conclusion: Daily scheduling and cyclic chemotherapy can be applied alternatively more effectively, by considering the interindividual variations in the pharmacokinetic effect (φ).
机译:>简介:有多种策略可以克服癌症化学疗法的主要弊端,例如毒性和耐药性。其中之一是通过优化给药前的药物调度科学计算。在大多数这些策略中,药效学变化比药代动力学变化更重要。这项研究旨在分析各个患者的药代动力学参数(φ)在癌症化疗方案中的重要性以及药效学因素。>方法:建立了数学模型并将其应用于开源OCTAVE GNU LINUX。通过使用OCTAVE中的优化工具来完成优化。本研究旨在评估化学疗法日程中常用的每日药物剂量和循环化学疗法。分析和不考虑药代动力学参数的四例。最佳疗法旨在在治疗结束时将癌细胞的数量减少到最少,并使耐药性癌细胞的出现最小化。由于剂量在容许的范围内,因此毒性作用也可以减至最小。>结果:即使考虑1%的作用(φ),最大剂量和性能指标也有所增加。每日排程。但是在循环疗法中,即使最大耐受剂量或性能指标未改变,累积毒性也大大降低。>结论:通过考虑以下因素,可以将日程安排和循环化疗更有效地交替使用个体之间的药代动力学效应(φ)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号